Skip to main
XOMA
XOMA logo

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is positioned for substantial revenue growth, with anticipated annual increases of over 20% through 2026, attributed to rising commercial sales from key products such as Vabysmo and new launches like Ojemda and Miplyffa. The company's total income from royalty agreements surged to $28.5 million in 2024, reflecting a significant leap from the $4.8 million recorded in 2023, bolstered by higher revenue from customer contracts and purchased receivables. Looking ahead, XOMA is projected to generate $49.0 million in revenues for 2026, with potential contributions from earlier-stage assets and milestone payments, further solidifying its positive financial outlook.

Bears say

XOMA Royalty Corp has experienced significant revenue and net earnings variability, primarily due to fluctuations in the international market for its products, which poses risks in light of potential economic downturns and changes in governmental policies. The company's operations could be adversely affected by factors such as failed clinical trials or inadequate funding for drug development, leading to heightened stock volatility. Additionally, XOMA's recent share price declines, following earlier gains, reflect broader market trends in the biotechnology sector, which could be further impacted by the departure of key executives with critical industry knowledge.

XOMA (XOMA) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 2 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.